CR20220452A - COMBINACIÓN DE UN INHIBIDOR DE BCL-2 Y UN INHIBIDOR DE MCL1, USOS Y COMPOSICIONES FARMACÉUTICAS DE ESTOS (Divisional del Expediente 2019-0022) - Google Patents

COMBINACIÓN DE UN INHIBIDOR DE BCL-2 Y UN INHIBIDOR DE MCL1, USOS Y COMPOSICIONES FARMACÉUTICAS DE ESTOS (Divisional del Expediente 2019-0022)

Info

Publication number
CR20220452A
CR20220452A CR20220452A CR20220452A CR20220452A CR 20220452 A CR20220452 A CR 20220452A CR 20220452 A CR20220452 A CR 20220452A CR 20220452 A CR20220452 A CR 20220452A CR 20220452 A CR20220452 A CR 20220452A
Authority
CR
Costa Rica
Prior art keywords
inhibitor
bcl
combination
mcl
pharmaceutical compositions
Prior art date
Application number
CR20220452A
Other languages
English (en)
Inventor
Donia Moujalled
Ana Leticia Maragno
Erick Morris
Sneha Sanghavi
Heiko Maacke
Youzhen Wang
Giovanna Pomilio
Ensar Halilovic
Prakash Mistry
Audrey Claperon
Andrew Wei
Olivier Geneste
Dale Porter
Original Assignee
Novartis Ag
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Servier Lab filed Critical Novartis Ag
Priority claimed from PCT/EP2017/068453 external-priority patent/WO2018015526A1/en
Publication of CR20220452A publication Critical patent/CR20220452A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Una combinación que comprende un inhibidor de BCL-2 y un inhibidor de MCL1, y composiciones y usos de ésta.
CR20220452A 2016-07-22 2017-07-21 COMBINACIÓN DE UN INHIBIDOR DE BCL-2 Y UN INHIBIDOR DE MCL1, USOS Y COMPOSICIONES FARMACÉUTICAS DE ESTOS (Divisional del Expediente 2019-0022) CR20220452A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16180918 2016-07-22
EP16306420 2016-10-28
US201762464554P 2017-02-28 2017-02-28
US201762517252P 2017-06-09 2017-06-09
PCT/EP2017/068453 WO2018015526A1 (en) 2016-07-22 2017-07-21 Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CR20220452A true CR20220452A (es) 2022-10-27

Family

ID=65524552

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20190022A CR20190022A (es) 2016-07-22 2017-07-21 Combinación de un inhibidor de blc-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de estos
CR20220452A CR20220452A (es) 2016-07-22 2017-07-21 COMBINACIÓN DE UN INHIBIDOR DE BCL-2 Y UN INHIBIDOR DE MCL1, USOS Y COMPOSICIONES FARMACÉUTICAS DE ESTOS (Divisional del Expediente 2019-0022)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20190022A CR20190022A (es) 2016-07-22 2017-07-21 Combinación de un inhibidor de blc-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de estos

Country Status (25)

Country Link
US (1) US20190240225A1 (es)
EP (1) EP3487499A1 (es)
JP (1) JP7050744B2 (es)
KR (1) KR102505218B1 (es)
CN (1) CN109789130A (es)
AU (1) AU2023202746A1 (es)
BR (1) BR112019001024A2 (es)
CA (1) CA3030967C (es)
CL (1) CL2019000144A1 (es)
CO (1) CO2019000596A2 (es)
CR (2) CR20190022A (es)
CU (1) CU20190002A7 (es)
DO (1) DOP2019000015A (es)
EC (1) ECSP19006687A (es)
GE (1) GEP20217301B (es)
IL (1) IL264261B2 (es)
MA (1) MA45718A (es)
MX (1) MX2019000919A (es)
NI (1) NI201900006A (es)
PH (1) PH12019500121A1 (es)
RU (1) RU2746705C2 (es)
SG (2) SG10202013206TA (es)
SV (1) SV2019005811A (es)
TN (1) TN2019000014A1 (es)
UA (1) UA125138C2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
CN115856302B (zh) * 2023-03-02 2023-06-02 北京大学人民医院 用于成熟b细胞肿瘤免疫分型的抗体组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
AU2023202746A1 (en) 2023-05-18
NI201900006A (es) 2019-05-10
ECSP19006687A (es) 2019-02-28
SV2019005811A (es) 2019-05-20
DOP2019000015A (es) 2019-05-15
MX2019000919A (es) 2019-08-29
BR112019001024A2 (pt) 2019-05-14
KR102505218B1 (ko) 2023-02-28
SG11201900402UA (en) 2019-02-27
GEP20217301B (en) 2021-10-11
CO2019000596A2 (es) 2019-02-08
JP2019528250A (ja) 2019-10-10
CL2019000144A1 (es) 2019-05-31
US20190240225A1 (en) 2019-08-08
IL264261B2 (en) 2023-05-01
RU2019104105A3 (es) 2020-09-28
PH12019500121A1 (en) 2019-09-30
CU20190002A7 (es) 2019-09-04
JP7050744B2 (ja) 2022-04-08
SG10202013206TA (en) 2021-02-25
CA3030967C (en) 2022-02-15
IL264261B1 (en) 2023-01-01
RU2746705C2 (ru) 2021-04-19
KR20190031291A (ko) 2019-03-25
CR20190022A (es) 2019-04-03
MA45718A (fr) 2019-05-29
EP3487499A1 (en) 2019-05-29
CN109789130A (zh) 2019-05-21
TN2019000014A1 (en) 2020-07-15
RU2019104105A (ru) 2020-08-24
UA125138C2 (uk) 2022-01-19
IL264261A (en) 2019-02-28
CA3030967A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2022004304A (es) Agentes inductores de apoptosis.
MX2016011556A (es) Composiciones que comprenden un agente amargante.
MX2016011558A (es) Composiciones que comprenden un agente amargante.
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX2017013073A (es) Inhibidores de grelina o-aciltransferasa.
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
MX2017013072A (es) Inhibidores de grelina o-aciltransferasa.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
TR201901228T4 (tr) Vortioksetin piroglutamat.
PH12019500121A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
JOP20180018A1 (ar) تركيبات صيدلية تتضمن مثبط jak
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
IN2014MU00916A (es)
IL283105A (en) Combination of MCL-1 inhibitor and midostearoin, its uses and pharmaceutical preparations
JOP20190159B1 (ar) توليفة من مثبط mcl-1 ومركب تاكسان، استخداماتها وتركيباتها الصيدلانية
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
EA201990305A1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
EA201991623A1 (ru) Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
MX2016013428A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.